ac 7700 profile

AC 7700: a vascular disrupting agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6918404
CHEMBL ID	585539
SCHEMBL ID	1419930
MeSH ID	M0350356

Synonym
rpr-258062a
cs-39-l-ser.hcl
ombrabulin hydrochloride
ac-7700 ,
ave-8062a
ac 7700
CHEMBL585539
D09787
ombrabulin hydrochloride (jan)
253426-24-3
ave 8062
propanamide, 2-amino-3-hydroxy-n-(2-methoxy-5-((1z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl)-, monohydrochloride, (2s)-
unii-kxz9ndo6h0
ave 8062a
kxz9ndo6h0 ,
ombrabulin hydrochloride [jan]
propanamide, 2-amino-3-hydroxy-n-(2-methoxy-5-((1z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl)-, hydrochloride (1:1), (2s)-
propanamide, 2-amino-3-hydroxy-n-(2-methoxy-5-((1z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl)-,monohydrochloride, (2s)-
SCHEMBL1419930
253609-44-8
DTXSID50426074
ombrabulin (hydrochloride)
CS-5451
HY-18256
AKOS030526753
(z)-n-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl] phenyl]-l-serinamide hydrochloride
(2s)-2-amino-3-hydroxy-n-[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide;hydrochloride
BCP29573
ac7700 (hydrochloride)
ave8062 (hydrochloride)
Q27282491
MS-27877

Excerpt	Reference	Relevance
" Close collaboration with cardiology colleagues for early indicators of serious cardiac adverse events will likely minimize toxicity while optimizing the therapeutic potential of VDAs and ultimately enhancing patient outcomes."	( Cardiovascular toxicity profiles of vascular-disrupting agents. Lenihan, DJ; Subbiah, IM; Tsimberidou, AM, 2011)	0.37
" The most frequent related adverse events in this group were diarrhea, nausea, and hypertension."	( An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N, 2014)	0.4

Excerpt	Reference	Relevance
" Safety, tumor response, pharmacokinetics, and pharmacodynamic biomarkers were evaluated."	( Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. Bahleda, R; Braghetti, A; Cohen, P; Delmonte, A; Farace, F; Hospitel, M; Lassau, N; Lorusso, P; Sessa, C; Soria, JC; Tolcher, A; Veyrat-Follet, C, 2013)	0.39
"To determine ombrabulin's maximum tolerated dose and dose recommended for Japanese patients with advanced solid tumors and to assess its antitumor activity and overall safety and pharmacokinetic profiles."	( An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N, 2014)	0.4
" Pharmacokinetic parameters were comparable to those in non-Japanese patients."	( An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N, 2014)	0.4
" The safety and pharmacokinetic profiles were comparable between Japanese and Caucasian patients (funded by Sanofi; ClinicalTrials."	( An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N, 2014)	0.4
" Pharmacokinetic analyses did not show any relevant drug interactions."	( A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours. Dieras, V; Eskens, FA; Fontaine, H; Hospitel, M; Oprea, C; Tosi, D; Tresca, P; Van der Gaast, A; Van Doorn, L; Veyrat-Follet, C, 2014)	0.4
" Ombrabulin clearance was high with a short terminal half-life and a medium volume of distribution."	( Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A, 2014)	0.4

Excerpt	Reference	Relevance
" Ombrabulin was combined with two standard taxane/platinum doublets in a phase I study to determine the recommended combination doses."	( Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A, 2014)	0.4
"5-35 mg/m2) in combination with docetaxel (60 or 75 mg/m2) and cisplatin (75 mg/m2), agents were administered 24 h apart every 3 weeks to Japanese patients with advanced solid tumors."	( Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors. Ecstein-Fraisse, E; Hida, T; Horiike, A; Horio, Y; Nishio, M; Satouchi, M; Sunaga, Y, 2018)	0.48

Excerpt	Relevance	Reference
" This combination effect was found over wide dosage ranges of AC-7700 (20-80 mg/kg) and CDDP (2."	( Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Ehara, S; Harada, K; Morinaga, Y; Nihei, Y; Suga, Y; Suzuki, M, 2003)	0.32

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Tubulin beta-2B chain	Bos taurus (cattle)	IC50 (µMol)	13.0000	0.2500	1.8838	8.7000	AID1278670
Similar to alpha-tubulin isoform 1	Bos taurus (cattle)	IC50 (µMol)	13.0000	0.2500	1.8779	8.7000	AID1278670
Similar to alpha-tubulin isoform 1	Bos taurus (cattle)	IC50 (µMol)	13.0000	0.2500	1.8656	8.7000	AID1278670
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
microtubule-based process	Tubulin beta-2B chain	Bos taurus (cattle)
nervous system development	Tubulin beta-2B chain	Bos taurus (cattle)
positive regulation of axon guidance	Tubulin beta-2B chain	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
GTPase activity	Tubulin beta-2B chain	Bos taurus (cattle)
metal ion binding	Tubulin beta-2B chain	Bos taurus (cattle)
protein heterodimerization activity	Tubulin beta-2B chain	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
microtubule cytoskeleton	Tubulin beta-2B chain	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1278682	Displacement of [3H]colchicine from bovine brain tubulin at 1 uM after 10 mins by scintillation counting analysis	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
AID1278670	Inhibition of bovine brain tubulin polymerization preincubated for 15 mins by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
AID1278675	Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by SRB assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
AID1278683	Displacement of [3H]colchicine from bovine brain tubulin at 5 uM after 10 mins by scintillation counting analysis	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
AID443467	Cytotoxicity against human HeLa cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24	Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs.
AID512071	Antitumor activity against mouse 3LL cells transplanted in to BALB/c mouse assessed as tumor growth inhibition at 80 mg/kg, ip qd for 4 days	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
AID1278672	Prodrug conversion assessed as porcine leucine aminopeptidase-mediated compound cleavage by HPLC analysis	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
AID1278673	Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
AID1278674	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by SRB assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
AID443468	Cytotoxicity against human MCF7 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24	Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs.
AID512072	Antitumor activity against mouse 3LL cells transplanted in to BALB/c mouse assessed as tumor growth inhibition at 40 mg/kg, ip twice a week	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
AID1278671	Activity at porcine leucine aminopeptidase by HPLC analysis	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (7.41)	18.2507
2000's	10 (37.04)	29.6817
2010's	15 (55.56)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	7 (25.00%)	5.53%
Reviews	5 (17.86%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	16 (57.14%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
ifosfamide [no description available]	4.41	1	1	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	12.36	24	7	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.06	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
sulfur hexafluoride Sulfur Hexafluoride: Sulfur hexafluoride. An inert gas used mainly as a test gas in respiratory physiology. Other uses include its injection in vitreoretinal surgery to restore the vitreous chamber and as a tracer in monitoring the dispersion and deposition of air pollutants.. sulfur hexafluoride : A sulfur coordination entity consisting of six fluorine atoms attached to a central sulfur atom. It is the most potent greenhouse gas currently known, with a global warming potential of 23,900 times that of CO2 over a 100 year period (SF6 has an estimated lifetime in the atmosphere of between 800 and 3,000 years).	2.05	1	0	sulfur coordination entity	greenhouse gas; NMR chemical shift reference compound; ultrasound contrast agent
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	3.48	1	1	elemental platinum; nickel group element atom; platinum group metal atom
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	4.4	1	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	2.03	1	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
combretastatin combretastatin: cytotoxic principle from South African tree COMBRETUM caffrum; structure given in first source; acts at COLCHICINE site of TUBULIN	4.37	3	0
vadimezan vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.	3.56	2	0	monocarboxylic acid; xanthones	antineoplastic agent
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	7.01	4	3	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
carboplatin [no description available]	4.4	1	1
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	5.61	7	0	stilbene
pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.	4.09	2	0	diphosphate ion
fosbretabulin [no description available]	2.76	3	0	stilbenoid
fosbretabulin fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source	4.72	5	0
combretastatin a-4 disodium phosphate [no description available]	2.46	2	0
soblidotin soblidotin: a dolastatin 10 derivative; RN refers to (2S-(1(1R(R),2S),2R(1S,2S)))-isomer; structure given in first source. soblidotin : A tetrapeptide derivative of dolastatin 10. It is an inhibitor of tubulin polymerization which exhibits potent antitumor activity.	3.15	1	0	tetrapeptide	antineoplastic agent; apoptosis inducer; microtubule-destabilising agent
oxi 4503 Oxi 4503: diphosphate prodrug of cambretastatin A1	4.09	2	0
taxane taxane: produced by Taxomyces andreanae	3.48	1	1	diterpene; terpenoid fundamental parent
ave-8063 AVE-8063: has both antivascular and antineoplastic activities; structure in first source	2.76	3	0
zd 6126 [no description available]	4.37	3	0
npi 2358 NPI 2358: antineoplastic; structure in first source. plinabulin : A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione substituted by benzylidene and (5-tert-butyl-1H-imidazol-4-yl)methylidene groups at positions 3 and 6, respectively. It is a vascular disrupting agent and a microtubule destabalising agent which was in clinical trials (now discontinued) for the treatment of non-small cell lung cancer.	3.16	1	0	2,5-diketopiperazines; benzenes; imidazoles; olefinic compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; microtubule-destabilising agent
verubulin verubulin: antineoplastic; a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps; structure in first source	2.06	1	0

Condition	Relationship Strength	Studies	Trials
Breast Cancer [description not available]	2.13	1	0
Benign Neoplasms [description not available]	10.07	11	4
Breast Neoplasms Tumors or cancer of the human BREAST.	2.13	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	10.07	11	4
Carcinoma, Non-Small Cell Lung [description not available]	5.4	2	2
Cancer of Lung [description not available]	6.47	5	2
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	5.4	2	2
Lung Neoplasms Tumors or cancer of the LUNG.	6.47	5	2
Adverse Drug Event [description not available]	3.47	1	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	3.47	1	1
Cancer of Gastrointestinal Tract [description not available]	3.01	1	0
Angiogenesis, Pathologic [description not available]	7.91	9	1
Metastase [description not available]	3.48	1	1
Local Neoplasm Recurrence [description not available]	3.48	1	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	3.48	1	1
Response Evaluation Criteria in Solid Tumors An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.	4.4	1	1
Sarcoma, Epithelioid [description not available]	4.76	2	1
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	4.76	2	1
B16 Melanoma [description not available]	2.05	1	0
Carcinoma, Epidermoid [description not available]	2.08	1	0
Cancer of Head [description not available]	2.08	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.08	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.08	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.69	3	0
Experimental Hepatoma [description not available]	2.41	2	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.41	2	0
Adenocarcinoma, Basal Cell [description not available]	2.01	1	0
Cancer of Colon [description not available]	2.01	1	0
Sarcoma 180 An experimental sarcoma of mice.	2.01	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.01	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.01	1	0
Reticulum Cell-Like Sarcoma, Yoshida [description not available]	3.33	2	0
Experimental Neoplasms [description not available]	2.93	4	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.02	1	0
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	2.02	1	0
Cancer of Ovary [description not available]	2.03	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.03	1	0
Lymph Node Metastasis [description not available]	2.41	2	0
Carcinoma, Anaplastic [description not available]	2.01	1	0
Cardiac Cancer [description not available]	2.01	1	0
Cancer of Kidney [description not available]	2.01	1	0
Cancer of Stomach [description not available]	2.01	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.01	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.01	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.01	1	0

ac 7700

Description

Cross-References

Synonyms (32)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Protein Targets (3)

Inhibition Measurements

Biological Processes (3)

Molecular Functions (3)

Ceullar Components (1)

Bioassays (12)

Research

Studies (27)

Market Indicators

Research Demand Index: 20.95

Study Types

ac 7700

Description

Cross-References

Synonyms (32)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Protein Targets (3)

Inhibition Measurements

Biological Processes (3)

Molecular Functions (3)

Ceullar Components (1)

Bioassays (12)

Research

Studies (27)

Market Indicators

Research Demand Index: 20.95

Study Types

Related Drugs (23)

Related Conditions (45)